Antares Pharma, Inc. (NASDAQ:ATRS) shot up 7.4% on Thursday . The company traded as high as $1.92 and last traded at $1.89. 866,696 shares were traded during mid-day trading, a decline of 45% from the average session volume of 1,573,358 shares. The stock had previously closed at $1.76.

A number of research firms have recently weighed in on ATRS. Piper Jaffray Companies set a $3.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Monday, October 23rd. HC Wainwright set a $5.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Vetr raised Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price for the company in a research note on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $3.84.

The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.

Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.01 million. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. equities analysts anticipate that Antares Pharma, Inc. will post -0.11 earnings per share for the current fiscal year.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. Corporate insiders own 11.60% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital Advantage Inc. bought a new position in Antares Pharma during the 3rd quarter valued at approximately $110,000. Alliancebernstein L.P. bought a new position in Antares Pharma during the 2nd quarter valued at approximately $119,000. Legal & General Group Plc bought a new position in Antares Pharma during the 2nd quarter valued at approximately $120,000. MML Investors Services LLC raised its position in Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Credit Suisse AG bought a new position in Antares Pharma during the 1st quarter valued at approximately $146,000. 36.84% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Antares Pharma, Inc. (ATRS) Shares Up 7.4%” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/16/antares-pharma-inc-atrs-shares-up-7-4.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.